Presentations in this session:

12:30 MoPpLB0101    Abstract HIV impairs reverse cholesterol transport from macrophages: a possible mechanism of atherogenic effect of HIV-1 infection Bukrinsky M.1, Mujawar Z.1, Rose H.2, Morrow M.P.1, Bobryshev Y.3, Orenstein J.1, Sviridov D.2 1George Washington University, Washington, United States, 2Baker Heart Research Institute, Melbourne, Australia, 3University of New South Wales, Sydney, Australia

12:35 MoPpLB0103    Abstract The optimal duration of treatment for HIV-infected patients with chronic hepatitis C (CHC) and genotype 2 or 3 is 48 WEEKS: results of a randomised controlled trial Zanini B.1, Puoti M.1, Quiros Roldan E.1, Quinzan G.P.2, Bella D.1, De Luca A.3, Rizzardini G.4, Bruno R.5, Carosi G.1, MASTER COINFECTION STUDY GROU 1Dept Infectious Diseases University of Brescia, Brescia, Italy, 2Dept Infectious Diseases Opsedali Riuniti Bergamo, Bergamo, Italy, 3Dept Infectious Diseases UCSC, Roma, Italy, 4Dept Infectious Diseases Ospedal

12:40 MoPpLB0104    Abstract Growth hormone therapy is associated with increased thymic mass and CD4+ T-cell recovery in HIV-infected adults: interim results of a randomized prospective study Napolitano L.A.1, Schmidt D.2, Gotway M.B.3, Filbert E.L.2, Ameli N.3, Ng M.2, Epling L.3, Sinclair E.3, Bacchetti P.3, McCune J.M.1 1Gladstone Institute of Virology and Immunology/UCSF, San Francisco, United States, 2Gladstone Institute of Virology and Immunology, San Francisco, United States, 3University of California, San Francisco, United States

12:45 MoPpLB0105    Abstract Methamphetamine use is associated with potential sexual transmission of drug-resistant HIV Chin-Hong P.1, Deeks S.G.1, Liegler T.2, Krone M.R.1, Grant R.M.2, Hecht F.1, Vittinghoff E.1, Coates T.3, Martin J.1 1University of California at San Francisco, San Francisco, United States, 2Gladstone Institutue of Virology and Immunology, San Francisco, United States, 3University of California at Los Angeles, Los Angeles, United States

12:50 MoPpLB0106    Abstract An HIV-1 triple recombinant of subtypes B, C and F in Buenos Aires, Argentina. Pando M.A.1, Eyzaguirre L.M.2, Segura M.1, Bautista C.T.2, Marone R.3, Sanchez J.L.2, Weissenbacher M.1, Carr J.K.2, Avila M.M.1 1National Reference Center for AIDS, Buenos Aires, Argentina, 2U.S. Military HIV Research Program (USMHRP) and the Henry M Jackson Foundation, Inc., Rockville, Maryland., United States, 3Nexo NGO., Buenos Aires, Argentina